EN DE
Watch GN Store Nord for free: we tell you when fair value or trend changes.
Data-driven stock valuation

GN Store Nord (GN) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of GN Store Nord stock DKK 98.66, price DKK 124, that is 20.2% below the price, quality 52 out of 100. Rating: overvalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare DK · ISIN DK0010272632

GS GN Store Nord logo Some data Nov 8, 2026

GN Store Nord

GN · CO
Solid, but expensive

Our calculation puts a fair price 20% below what the stock costs today.

Generates free cash flow
Upbeat coverage
Quality 52/100
Loss over the last twelve months · -1.9% net margin (TTM) · fiscal year 2025 3.9%
Moderate debt
Mixed vs. peers (6/13)
Some data
Revenue last quarter 43% below a year ago.
Fair value kr 98.66 · Overvalued (−20.2%)
Weak Growth (revenue 3y −3.3 %/yr in DKK)
Narrow moat 36/100 · thin data
Watch GN Store Nord for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 560.96 kr 82.56 Fair Value kr 98.66 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

60‑month range kr 82.56 – kr 560.96 · fair‑value band kr 73.99 – kr 141.55 · the kr 123.65 price screens above the kr 98.66 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 8, 2026.

Follow GN Store Nord in your weekly email

Every Wednesday you see whether GN Store Nord is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

GN Store Nord A/S provides hearing, audio, video, and gaming solutions in Denmark, Europe, North America, and internationally. The company operates through Hearing, Enterprise, and Gaming segments. The Hearing segment produces and sells hearing instruments and products.

Show moreShow less

The Enterprise segment supplies audio and video devices for professional use. The Gaming segment produces gaming devices and peripherals. It offers its products under the ReSound, Beltone, Interton, Danavox, Jabra Enhance, Jabra, BlueParrott, FalCom, SteelSeries, and KontrolFreek brands.

GN Store Nord A/S was founded in 1869 and is based in Ballerup, Denmark.

Stock analysis

GN Store Nord (GN) currently trades at kr 123.65, while our model-based Fair Value estimate is kr 98.66, 20% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of kr 212.51 per share, and 11 of the 24 models we run sit above the kr 123.65 price.

Bear case: the Earnings-Based group reads lowest at kr 43.67, and 13 of the 24 models stay below the price. Data coverage for this calculation is medium.

Scenario range: kr 73.99 (bear) to kr 141.55 (bull), the price of kr 123.65 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

GN Store Nord reported revenue of 16.9B DKK in FY2025 versus 15.8B DKK in FY2021, a compound +1.7%/yr. Reported net income was 653M DKK in FY2025, compounding −21.9%/yr from FY2021.

Key figures

Market cap 18.0B DKK (≈ $2.7B) Mid · P/S ratio 1.22 · EPS (TTM) kr −1.15 · Dividend yield 0.5% · Net margin −1.9% · Return on equity 2.6% · Return on assets (EBIT) 5.8% (5-year average) · Operating margin 13.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 36 out of 100 (low confidence).

What moves the price

The share trades at its 52-week high and 43% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at −20%, GN screens richer than that median.

Fair Value models

Bear kr 73.99 Fair Value kr 98.66 Bull kr 141.55
Price kr 123.65 · Downside -20.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF kr 162.44 kr 269.23 kr 418.79 77
Growth DCF kr 163.69 kr 255.73 kr 376.01 75
EPV kr 41.44 kr 54.74 kr 65.96 74
All 24 models by family
DCF Models
FCF DCF kr 162.44 kr 269.23 kr 418.79 77
Owner Earnings kr 118.97 kr 204.04 kr 323.16 72
5Y Revenue Exit kr 97.21 kr 167.11 kr 254.21 69
5Y EBITDA Exit kr 151.82 kr 270.51 kr 408.77 71
5Y P/E Exit kr 71.18 kr 117.80 kr 165.22 68
10Y Revenue Exit kr 117.72 kr 185.63 kr 273.97 64
10Y EBITDA Exit kr 153.61 kr 253.35 kr 385.76 65
10Y P/E Exit kr 105.16 kr 153.34 kr 209.61 62
Earnings-Based
Graham-Dodd kr 30.49 kr 101.03 kr 135.17 62
Lynch FV kr 22.82 kr 32.60 kr 42.38 59
PEG = 1.0 kr 22.82 kr 32.60 kr 42.38 55
EPV kr 41.44 kr 54.74 kr 65.96 74
Dividend Discount
Gordon GGM kr 4.74 kr 8.83 kr 12.53 65
DDM Multi-Stage kr 4.74 kr 7.70 kr 9.40 65
Multiples
P/E Multiple kr 73.99 kr 98.66 kr 123.32 63
P/S Multiple kr 57.18 kr 76.24 kr 95.30 58
EV/EBIT kr 89.88 kr 142.80 kr 195.71 64
EV/EBITDA kr 151.93 kr 225.53 kr 299.13 66
EV/Revenue kr 44.44 kr 92.99 kr 141.55 51
Growth DCF
Growth DCF kr 163.69 kr 255.73 kr 376.01 75
Rev-Margin DCF kr 97.21 kr 169.29 kr 254.41 69
Economic Profit
Residual Income kr 56.53 kr 56.63 kr 60.38 74
ROIC Compounder kr 41.44 kr 54.74 kr 65.96 70
Growth Earnings
Growth-Adj P/E kr 62.22 kr 88.88 kr 115.55 65

Open the full fair value analysis →

Quality Score breakdown

Overall quality 52/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 35
How much profit the company makes from its sales and capital
Quality Growth 26
Are margins and returns getting better?
Cashflow 81
Do the profits arrive as real cash?
Financial strength 37
Debt, balance sheet and risk of trouble
Investment 72
Does it invest with discipline instead of growing at any price?
Low Volatility 31
How calm the share price moves, does not count
Price momentum 60
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 73
Distance to the 52-week high, does not count
New shares 74
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−6.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.6%
Start year 2020 (pandemic). Over 10 years: +7.2% a year
Revenue growth 25 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.6%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−15.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year−16.4%
Dividend (yield on the price)0.5%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−16.4% vs −1.4%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.12% → 11%
Pace: the 5-year rate starts in 2020 (pandemic)

Growth Forecast

A lot of optimism in the price
The price assumes less growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−0.1%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
−7.9%
Yearly sales growth analysts expect, extended to five years.
After inflation (Denmark: IMF forecast 2.1% a year to 2030, 2.0% from 2016 to 2025) that is about −2.1% a year for the price and −9.8% for the forecasts.
Forecast 2026 (sales)−43.4%
Forecast 2027 (sales)+4.5%
Projected 2028 (sales)+4.2%
Projected 2029 (sales)+3.9%
Projected 2030 (sales)+3.6%

GN screens overvalued: fair value 20% below the price. Compare with Abbott Laboratories, →

Earlier news

News mood ⓘNews mood, the average tone of recent news (65 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
Note from the team Oct 24, 2026
AI conclusion: The business shows strength in launching innovative products like Evolve3 and Nova Pro Omni that boost gross margins, yet its main weakness lies in thin signals of lasting advantage amid heavy channel investments pressuring adjusted margins.
Main risk: Continued front-loaded channel investments in a challenging market environment risk outpacing revenue gains and hitting near-term adjusted margins.
GN Store Nord is channeling significant resources into fresh product launches like Evolve3 headsets in Enterprise and Nova Pro Omni in Gaming to drive second-half momentum. These front-loaded channel investments have pressured near-term adjusted margins despite rising gross margins from the new offerings themselves. Will the expected revenue pickup and margin gains from this innovation push outweigh the costs in a still-challenging market environment, or will the spending continue to outpace results?
Join the discussion →

Compare GN Store Nord with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 320 stocks

Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 52 · Below median
Fair Value upside −20.2% · Above median
Profitability
Return on equity (12 months) 2.6% · Below median
Return on assets 2.2% · Above median
Net margin (12 months) −1.9% · Below median
Operating margin (12 months) 13.7% · Above median
Growth and dividend
Revenue growth (quarter YoY) −42.7% · Bottom 25%
Dividend yield (12 months) 0.5% · Bottom 25%
Balance sheet
Debt / equity 0.79× · Highest 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 1.65× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months) 1.22× · Cheapest 25%
Price / free cash flow (fiscal year) 7.1× · Cheapest 25%
EV/EBITDA 9.2× · Cheapest 25%
PEG 2.23× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)6 · sector 6
FUTURE (revenue growth)0 · sector 35
PAST (return on equity)10 · sector 17
HEALTH (low debt)61 · sector 98
DIVIDEND (yield)9 · sector 34

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Stryker Corporation SYK $325.87 $358.46 +10% vs GN
Boston Scientific Corporation BSX $42.75 $47.03 +10% vs GN
DexCom, Inc DXCM $79.41 $87.35 +10% vs GN
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥184.15 ¥197.22 +7% vs GN
GE HealthCare Technologies Inc GEHC $82.38 $69.92 −15% vs GN
Edwards Lifesciences Corporation EW $102.14 $81.94 −20% vs GN
Siemens Healthineers AG SHL €44.66 €34.95 −22% vs GN
Abbott Laboratories, ABT $109.93 $75.28 −32% vs GN
Medtronic plc MDT $101.80 $65.61 −36% vs GN
Koninklijke Philips N.V PHIA €27.33 €15.23 −44% vs GN

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

GN Store Nord: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "GN Store Nord Fair Value". https://www.fairvalue-calculator.com/stock/GN

Frequently asked questions

Is GN Store Nord (GN) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of kr 98.66 versus a price of kr 123.65, about 20% lower (overvalued).
What is the fair value of GN?
Our model-based fair value for GN Store Nord is kr 98.66 (as of Nov 8, 2026), built from audited fundamentals. The current price: kr 123.65.
What is the quality score of GN?
GN Store Nord has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for GN Store Nord (GN)?
Our model-based price target is the fair value of kr 98.66 (as of Nov 8, 2026) from 24 valuation models. Cautious scenario kr 73.99, optimistic scenario kr 141.55. It is a calculation from audited fundamentals, not an analyst target.
What is the GN Store Nord stock forecast for 2026?
Our models put fair value at kr 98.66, about 20% lower versus a price of kr 123.65 (overvalued). Cautious scenario kr 73.99, optimistic scenario kr 141.55. The calculation is refreshed regularly with new filings.
What is the revenue of GN Store Nord (GN)?
GN Store Nord reported trailing-twelve-month revenue of about 14.8B DKK (latest available figure, as of Nov 8, 2026).
Does GN Store Nord pay a dividend?
GN Store Nord currently shows a dividend yield of 0.47% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of GN Store Nord (GN)?
GN Store Nord has a dividend yield of 0.5%.
What growth is priced into GN Store Nord (GN)?
For today's price to be fair in a discounted-cash-flow model, GN Store Nord would have to grow free cash flow by -0.1 % per year for five years (discount rate 10.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +4.7 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of GN use?
Our models discount GN Store Nord at 10.4 %: a base by market capitalisation (mid), damped by beta 1.40, country premium for Denmark. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For GN Store Nord that is -0.1 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.4 %) and the same formula as our fair value.
How much growth has GN Store Nord (GN) delivered so far?
Over the past 5 years revenue at GN Store Nord grew +4.7 % a year. The price currently implies free-cash-flow growth of -0.1 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of GN Store Nord (GN) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into GN Store Nord (-0.1 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of GN Store Nord (GN)?
The free-cash-flow yield on the price is 14.04 %: that much free cash flow GN Store Nord produces per unit of market value. When it exceeds the discount rate of our models (10.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of GN Store Nord (GN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For GN Store Nord it is kr 98.66 per share (as of Nov 8, 2026), against a price of kr 123.65. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Growth DCF, Economic Profit, Growth Earnings).
Is GN Store Nord stock overvalued or undervalued in 2026?
As of Nov 8, 2026, GN trades above its calculated fair value: price kr 123.65, fair value kr 98.66, a gap of about −20% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of GN?
No. The price is what the market pays today (kr 123.65); the fair value is what the company's own numbers justify (kr 98.66). For GN Store Nord the two are kr 24.99 per share apart. That gap is exactly why we show both numbers side by side.
How much is GN Store Nord worth?
The market values GN Store Nord at about 18.0B DKK (market capitalisation, as of Nov 8, 2026). Per share that is kr 123.65; our models calculate a fair value of kr 98.66 per share.
What do the bullish and bearish scenarios say about GN?
Our models span a range for GN Store Nord: cautious scenario kr 73.99, base kr 98.66, optimistic kr 141.55 per share (as of Nov 8, 2026, price kr 123.65). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of GN?
The PEG ratio of GN Store Nord is 2.23 (P/E divided by earnings growth, as of Nov 8, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of GN Store Nord (GN)?
Balance-sheet figures for GN Store Nord (as of Nov 8, 2026): return on equity 2.6%, debt of 0.79 per unit of equity. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
How far is GN from its 52-week high?
GN Store Nord trades at kr 123.65, at its 52-week high of kr 124.00 and 43% above the low of kr 86.50 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of kr 98.66 is for.
Which stocks are comparable to GN Store Nord?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is GN Store Nord stock attractive at the current price?
The data as of Nov 8, 2026: price kr 123.65, calculated fair value kr 98.66 (−20%), Quality Score 52/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of GN calculated?
We run GN Store Nord through 24 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of kr 98.66 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. GN Store Nord itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of GN Store Nord (GN)?
The closing price on Nov 6, 2026 was kr 123.65. Our model-based fair value is kr 98.66, about 20% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with GN Store Nord right now?
Solid but not exceptional quality (52/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (kr 73.99 to kr 141.55) leaves room in how you read the outcome.
Where does the earnings growth of GN Store Nord (GN) come from?
Earnings per share at GN Store Nord grew −2.8 % a year from 2014 to 2025. Broken into its drivers: revenue per share +10.0 %, EBIT margin −6.6 %, tax rate +0.3 %, residual (interest, one-offs) −5.7 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of GN Store Nord

How large is the market capitalisation of GN Store Nord (GN)?
The market capitalisation of GN Store Nord is 18.0B DKK (≈ $2.7B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of GN Store Nord (GN)?
The price-to-sales ratio of GN Store Nord is 1.22 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of GN Store Nord (GN)?
Earnings per share at GN Store Nord are kr −1.15. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of GN Store Nord (GN)?
The dividend yield of GN Store Nord is 0.5%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of GN Store Nord (GN)?
The net margin of GN Store Nord is −1.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of GN Store Nord (GN)?
The return on equity (ROE) of GN Store Nord is 2.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of GN Store Nord (GN)?
On an EBIT basis the return on assets of GN Store Nord is 5.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of GN Store Nord (GN)?
The operating margin of GN Store Nord is 13.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at GN Store Nord (GN)?
Revenue at GN Store Nord is growing −42.7% versus a year earlier (3y avg −3.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at GN Store Nord (GN)?
Earnings per share at GN Store Nord are growing +384% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does GN Store Nord (GN) carry?
The net debt of GN Store Nord is 10.0B DKK (fiscal year 2025, ≈ 4.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch GN Store Nord in the live analysis

One click puts GN Store Nord on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.